5HT3	5hydroxytryptamine receptor;
A53T Tg	A53T α-Syn mutant transgenic mice;
AIFs	apoptosis-induced factors;
AKT	protein kinase B;
AP-1	activator protein 1;
AT	classic or general acupuncture;
Bax	Bcl-2 associated X;
Bcl2	B-cell lymphoma 2;
BV	Bee venom;
BVA	bee venom acupuncture;
bvPLA2	bee venom phospholipase A2;
CCI	chronic constriction injury;
CD14	cluster of differentiation 14;
CD206	cluster of differentiation 206;
Cdc42	cell division cycle protein 42;
CIA	collagen-induced arthritis;
CIPN	chemotherapy-induced peripheral neuropathy;
COX-2	cyclooxygenase-2;
Cyt C	cytochrome c;
DBV	dilute bee venom;
DC	dendritic cells;
DR	death receptor;
EAE	experimental autoimmune encephalomyelitis;
EGFR	epidermal growth factor receptor;
EndoG	endonuclease G;
EP2	prostaglandin E2 receptor 2;
ERK	extracellular regulated protein kinases;
ERK/p38 MAP	extracellular regulated protein kinases/p38 mitogen-activated protein kinases;
ERKs	extracellular regulated protein kinases;
Foxp3	forkhead box P3;
GPCRs	G protein-coupled receptors;
ICR mice	introduction of C57BL6 mouse;
IENFs	intraepidermal nerve fibers;
IFN	interferon;
IgE	immunoglobulin E;
IKK	IkB kinase;
IL-10	interleukin-10;
IL-17	interleukin-17;
IL-17A	interleukin-17 A;
IL-1β	interleukin-1β;
IL-4	interleukin-4;
IL-6	interleukin-6;
IL-8	interleukin-8;
iNOS	induced nitric oxide synthase;
iNOS	inducible nitric oxide synthase;
IVDD	intervertebral disc disease;
IκB	inhibitor of nuclear factor kappa B;
IκB	inhibitor of nuclear factor kappa B;
JNK	c-Jun N-terminal kinase;
M1	M1 microglia produce toxic substances to neurons;
M2	M2 microglia produce anti-inflammatory and tissue repair factors to promote survival and repair;
MAC-1	macrophage-1 antigen;
MAPK	p38 mitogen-activated protein kinase;
MBP	myelin basic protein;
MCP-1	monocyte chemotactic protein-1;
MEL	melittin;
MIP	macrophage inflammatory protein;
MMP-9	matrix metalloproteinase-9;
MMP-9	matrix metalloproteinase-9;
MPTP	1-me+7:116thyl-4-phenyl-1,2,3,6-tetrahydropyridine;
MTX	methotrexate;
NA1	nonacupoint 1;
NA2	nonspecific acupoints near ST36;
NA3 and NA4	nonspecific acupoints away from ST36;
NECK	the neck region;
NF-κB	nuclear factor kappa B;
NP	nucleus proprius;
P38	p38 mitogen-activated protein kinases;
PDQL	Parkinson’s Disease Quality of Life Questionnaire;
PGE2	prostaglandin E2;
PGE2	prostaglandin E2;
PIGD	postural instability gait difficulty;
PKB	phosphoinositide 3-kinases/protein kinase B;
PLA2	phospholipase A2;
PNQ	Patient Neurotoxicity Questionnaire;
RA	rheumatoid arthritis;
RAC1	ras-related C3 botulinum toxin substrate 1;
ROS	reactive oxygen species;
SDH	superficial dorsal horn;
SNpc	substantia nigra pars compacta;
Th1	T helper cell type 1;
TLR2	Toll-like receptors;
TLRs	toll-like receptors;
TMA	trimellitic anhydride;
TNF-α	tumor necrosis factor-α;
Treg	regulatory T cells;
UPDRS	Unified Parkinson’s Disease Rating Scale;
VAS	visual analog scale;
WOMAC	Western Ontario and McMaster Universities Arthritis Index;
α-syn	α-synuclein.